Basophil Activation Test Predicts Pediatric Wheezing Prognosis

Basophils are important immune cells that are involved in allergic diseases including asthma. CD63-based basophil activation tests (BATs) are a useful tool for not only identifying specific allergens, but also monitoring immunologic homeostasis. BATs are used for diagnosing food and drug allergies with high specificity and sensitivity.

A team of Pediatricians at the Shanghai Jiao Tong University School of Medicine (Shanghai, China) conducted a prospective cohort observation trial from July 2017 to March 2018 and enrolled children aged under five years with a convincing history of wheezing episodes (confirmed by the team or documented as “expiratory wheeze” in previous medical records). All enrolled subjects participated in specific immunoglobulin E (sIgE) testing. Serum samples were measured via the DX-Blot 45 Automatic Western Blotting instrument (Hangzhou Zhejiang Dixun Biological Genetic Engineering Co., Ltd. Hangzhou, Zhejiang, China).

The scientists collected anti-coagulated peripheral blood and stored at 2–8 °C for up to 6 hours. The Basophil Activation Test Set (Bühlmann Laboratories, Schönenbuch, Switzerland) was used for the BAT. In vitro stimulation was performed using an inhalant mix (Bühlmann Laboratories) that included common inhalation allergens (GX1, G12, T3, T4, W6, W9, M6, D1, D2, E1, and E2) as specific antigens. After processing and the red blood cells were lysed, the cells were resuspended in phosphate-buffered saline and assessed with a CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA). The test result was considered positive when the level of CD63 expression in stimulated cells was >15% over the baseline level.

The investigators reported that of the 45 originally enrolled children, 38 completed both the follow-up and a BAT. After stimulation with the inhalant mixture, the CD63 expression on basophils and the rate of positive CD63-based BAT results in children diagnosed with asthma were both significantly higher than those in children who were not diagnosed with asthma. For the prediction of asthma, the positive predictive value and negative predictive value of CD63-based BAT was 71.8 and 69.2%, respectively. The positive likelihood ratio and negative likelihood ratio of CD63-based BAT were 1.70 and 0.3, respectively.

The authors concluded that their study indicates that CD63-based BAT has potential clinical value for predicting asthma outcome in young children with wheezing episodes. The study was published on January 6, 2021 in the journal BMC Immunology.

Related Links:
Shanghai Jiao Tong University School of Medicine
Hangzhou Zhejiang Dixun Biological Genetic Engineering Co
Bühlmann Laboratories
Beckman Coulter